UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF l934
Eucrates Biomedical Acquisition Corp.
(Exact name of Registrant as specified in its charter)
British Virgin Islands | N/A | |
(State of incorporation or organization) | (I.R.S. Employer Identification No.) | |
250 West 55th Street, Suite 13D | ||
New York, New York | 10019 | |
(Address of principal executive offices) | (Zip Code) | |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class | Name of each exchange on which | |
to be so registered | each class is to be registered | |
Units, each consisting of one ordinary share, no par value, and one-third of one Warrant
Ordinary shares, no par value
Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share | The NASDAQ Stock Market LLC
The NASDAQ Stock Market LLC
The NASDAQ Stock Market LLC | |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box. ¨
Securities Act registration statement file number to which this form relates: 333-249333.
Securities to be registered pursuant to Section 12(g) of the Act:
N/A
(Title of Class)
Item 1. Description of Registrant’s Securities to be Registered.
The securities to be registered hereby are units, ordinary shares, and warrants to purchase ordinary shares, of Eucrates Biomedical Acquisition Corp. (the “Registrant”). The description of the units, ordinary shares and warrants set forth under the heading “Description of Securities” in the Registrant’s prospectus forming part of its Registration Statement on Form S-1 (File No. 333-249333), originally filed with the Securities and Exchange Commission on October 6, 2020, as thereafter amended and supplemented from time to time (the “Registration Statement”) to which this Form 8-A relates is incorporated by reference herein. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that is subsequently filed is hereby also incorporated by reference herein.
Item 2. Exhibits.
The following exhibits have been filed as exhibits to the Registration Statement, as amended, and are incorporated herein by reference:
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: October 22, 2020 | Eucrates Biomedical Acquisition Corp. | |||
By: | /s/ Parag Saxena | |||
Name: | Parag Saxena | |||
Title: | Chief Executive Officer |